NICE shuns Novo Nordisk's obesity med Saxenda, citing CV questions

Novo Nordisk bet big on its GLP-1 med Saxenda in obesity, despite rivals' failures to expand the global market. But payers in England have put up a roadblock that could hurt the Danish drugmaker's sales efforts. NICE rejected Saxenda for use on England's NHS, citing its list price and lack of long-term efficacy data in draft guidance published Friday.